医学
缓和医疗
止痛药
类阿片
重症监护医学
生活质量(医疗保健)
护理部
初级保健
护理研究
疼痛管理
临终关怀
梅德林
获得药品
质量(理念)
质量管理
卫生服务研究
类阿片流行病
家庭医学
阿片剂替代治疗
医疗急救
药品
临终关怀
慢性疼痛
病入膏肓
阿片相关疾病
疗养院
基本药物
作者
Yi Fan,Zhuojun Ye,Minmin Jiang,Limei Jing,Huiwen Zhang,Zhiyu Tang,Hongwei Qiao,Xinyun Wang,Xiaoyu Zhang,Youyang Tang,Lingyun Liu
标识
DOI:10.1007/s00520-026-10484-6
摘要
PURPOSE: To assess opioid consumption, availability, and policy alignment for cancer-related pain management in primary health care (PHC)-based inpatient hospice and palliative care (HPC) services in China. METHODS: A multicomponent analysis was conducted, including (1) a cross-national comparison of opioid consumption using International Narcotics Control Board (INCB) data (2020-2022); (2) a census-based assessment of opioid stocking and use in all PHC institutions providing inpatient HPC in a provincial system (2019-2023); and (3) a policy review comparing national Essential Medicines List (EML) with international recommendations. Opioid use was standardized as defined daily doses per million inhabitants per day (S-DDDpm). RESULTS: China's mean opioid consumption (168 S-DDDpm) was less than half the Asian average (368 S-DDDpm) and far below comparable economies. From 2019 to 2023, the proportion of PHC institutions stocking strong opioids rose from 22.5% to 30.2%, yet total consumption declined from 240.3 to 145.3 S-DDDpm (compound annual growth rate: -11.8%). Regional disparities existed. The national EML included only morphine, omitting most internationally recommended strengths and dosage forms. CONCLUSION: Opioid access for cancer-related pain management in China's PHC-based HPC services remains critically inadequate. Expanding essential drug formularies, diversifying formulations, and strengthening PHC prescribing capacity are urgent priorities to reduce disparities and improve quality of life for patients with advanced cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI